Starjemza's inclusion in Cost Plus Drugs' portfolio aims to challenge traditional specialty medication economics and enhance ...
Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) today announced the addition of Starjemza®, a new biosimilar medication, to its growing portfolio of affordable prescription drugs. Starjemza® ...
GoodRx, a prescription savings company, launched a new offering on Monday that delivers a cost-plus pricing model for independent pharmacies. Santa Monica, California-based GoodRx helps consumers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback